The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

BOCOM INTL: The medical insurance work conference again mentioned the Class B catalog and support for the development of commercial insurance, focusing on opportunities related to policy easing.

Recently, the pharmaceutical Sector has experienced a significant fluctuation followed by a decline. Considering that the Sector's valuation is still at a historical low, coupled with the upcoming bullish policies related to finance and medical insurance/commercial insurance and improved liquidity, this institution believes there is still room for further recovery.

Zhitong FinanceDec 19 09:31

[Brokerage Focus] BOCOM INTL expects commercial insurance to further develop by 2025, assisting in resolving payment issues for Innovative Drugs.

Jinwu Finance | BOCOM INTL expects that by 2025, commercial insurance will likely develop further, helping to solve payment issues for Innovative Drugs. At the same time, an innovative payment mechanism differentiated between Category B catalog and commercial insurance may alleviate the difficulties faced by Innovative Drug and device companies in entering hospitals and obtaining reimbursement. Recently, the pharmaceutical Sector has seen a significant decline after substantial fluctuations. Considering that the sector's valuation remains at historical lows, coupled with the introduction of favorable policies related to finance and medical insurance/commercial insurance, as well as improved liquidity, the bank believes there is still potential for further recovery. The bank continues to recommend potential beneficiary symbols of subsequent policy space, including: 1) AKESO (09926), Legend Health.

Jingwu Financial NewsDec 19 08:56

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 14:21

BOCOM INTL: Assigns a "Leading" rating to the domestic Pharmaceutical Industry. Shanghai establishes a 10 billion yuan M&A Fund, which is beneficial for accelerating industry consolidation.

BOCOM INTL believes that the pharmaceutical Sector still has further room for recovery.

Zhitong FinanceDec 12 10:20 · Ratings

Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities

BreakingsDec 12 07:38